H. Pylori and Autoimmune Disorders: Unraveling the Links between Chronic Infection and Immune Dysfunction: Review Paper
Main Article Content
Abstract
The human stomach is home to the Gram-negative bacterium Helicobacter pylori, which has been connected to several gastrointestinal disorders. There may be a link between H. pylori infection and the start of autoimmune disorders, according to recent research. This review examines the intricate connections between persistent H. pylori infection, immune system dysregulation, and their possible role in initiating autoimmune disorders. The study begins with a summary of H. pylori infection and its prevalence worldwide, emphasizing the mounting data that connects this bacterium to autoimmune disorders. Then, using experimental data from animal models and epidemiological research as support, it undertakes a thorough review of autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and autoimmune gastritis linked to H. pylori infection. The review looks at the clinical consequences and existing treatments, emphasizing how important it is to screen for and diagnose H. pylori infection in patients with autoimmune disorders. Moreover, current studies are looking into possibly using H. pylori removal as a therapeutic approach to lessen autoimmune symptoms.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Shirani M, Pakzad R, Haddadi MH, Akrami S, Asadi A, Kazemian H, et al. The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis. BMC Infectious Diseases. 2023;23(1):543.
II. de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World journal of gastroenterology. 2019;25(37):5578.
III. Khoder G, Muhammad JS, Mahmoud I, Soliman SSM, Burucoa C. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. Pathogens. 2019;8(2).
IV. Al-Karawi AS, Atoom AM, Al-Adwan SM, Adwan SW. Assessment of selected biochemical and immunological parameters after treatment by Cosmetic Procedures. Journal of Population Therapeutics and Clinical Pharmacology. 2023;30(2):201-13.
V. Kadhim AS, Al-Karawi AS. Insights into the Pathogenesis, Virulence Factors, and Diagnosis of Helicobacter pylori: A Comprehensive Review. American Journal of Bioscience and Bioinformatics. 2023;2(1):31-7.
VI. Hasni SA. Role of Helicobacter pylori infection in autoimmune diseases. Curr Opin Rheumatol. 2012;24(4):429-34.
VII. Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause or bystander. World J Gastroenterol. 2014;20(3):613-29.
VIII. Richard-Eaglin A, Smallheer BA. Immunosuppressive/Autoimmune Disorders. Nurs Clin North Am. 2018;53(3):319-34.
IX. Cadamuro AC, Rossi AF, Maniezzo NM, Silva AE. Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs. World J Gastroenterol. 2014;20(6):1424-37.
X. Moyat M, Velin D. Immune responses to Helicobacter pylori infection. World J Gastroenterol. 2014;20(19):5583-93.
XI. Wang L, Cao ZM, Zhang LL, Dai XC, Liu ZJ, Zeng YX, et al. Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems. Front Immunol. 2022;13:833424.
XII. Culquichicón-Sánchez C, Correa R, Flores-Guevara I, Espinoza Morales F, Mejia CR. Immune Thrombocytopenic Purpura and Gastritis by H. pylori Associated With Type 1 Diabetes Mellitus. Cureus. 2016;8(2):e512.
XIII. Ramachandran L, Baloch L, Djirdeh TM, Sidhu Y, Gentile N, Affinati M. Immune thrombocytopenic purpura secondary to Helicobacter pylori. Proc (Bayl Univ Med Cent). 2022;35(1):60-1.
XIV. Cellini M, Santaguida MG, Virili C, Capriello S, Brusca N, Gargano L, et al. Hashimoto’s Thyroiditis and Autoimmune Gastritis. Frontiers in Endocrinology. 2017;8.
XV. Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C. Autoimmune thyroid diseases and Helicobacter pylori: the correlation is present only in Graves's disease. World J Gastroenterol. 2012;18(10):1093-7.
XVI. Choi YM, Kim TY, Kim EY, Jang EK, Jeon MJ, Kim WG, et al. Association between thyroid autoimmunity and Helicobacter pylori infection. Korean J Intern Med. 2017;32(2):309-13.
XVII. Etchegaray-Morales I, Jiménez-Herrera EA, Mendoza-Pinto C, Rojas-Villarraga A, Macías-Díaz S, Osorio-Peña Á D, et al. Helicobacter pylori and its association with autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis and Sjögren syndrome. J Transl Autoimmun. 2021;4:100135.
XVIII. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.
XIX. Al-Karawi AS, Alawssi YF, Khadhum MK. Immunological Insights into Rheumatoid Arthritis: A Comprehensive Review of Diagnosis and Assessment Approaches. African Journal of Advanced Pure and Applied Sciences (AJAPAS). 2023:151-9.
XX. Lee TH, Wu MC, Lee MH, Liao PL, Lin CC, Wei JC. Influence of Helicobacter pylori infection on risk of rheumatoid arthritis: a nationwide population-based study. Sci Rep. 2023;13(1):15125.
XXI. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica. 2011;6(4):330.
XXII. Rovenský J, Tuchyňová A. Systemic lupus erythematosus in the elderly. Autoimmunity reviews. 2008;7(3):235-9.
XXIII. Kamen DL. Environmental influences on systemic lupus erythematosus expression. Rheum Dis Clin North Am. 2014;40(3):401-12, vii.
XXIV. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481-90.
XXV. Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2010;1(4):163-75.
XXVI. Wu MC, Leong PY, Chiou JY, Chen HH, Huang JY, Wei JC. Increased Risk of Systemic Lupus Erythematosus in Patients With Helicobacter pylori Infection: A Nationwide Population-Based Cohort Study. Front Med (Lausanne). 2019;6:330.
XXVII. Lenti MV, Rugge M, Lahner E, Miceli E, Toh BH, Genta RM, et al. Autoimmune gastritis. Nat Rev Dis Primers. 2020;6(1):56.
XXVIII. Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochenschr. 2016;166(13-14):424-30.
XXIX. Toh BH, Chan J, Kyaw T, Alderuccio F. Cutting edge issues in autoimmune gastritis. Clin Rev Allergy Immunol. 2012;42(3):269-78.
XXX. Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013;11(6):385-99.
XXXI. Peek RM, Jr., Fiske C, Wilson KT. Role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiol Rev. 2010;90(3):831-58.
XXXII. Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins. 2019;11(11):677.
XXXIII. Suarez G, Reyes VE, Beswick EJ. Immune response to H. pylori. World J Gastroenterol. 2006;12(35):5593-8.
XXXIV. Larussa T, Leone I, Suraci E, Imeneo M, Luzza F. Helicobacter pylori and T Helper Cells: Mechanisms of Immune Escape and Tolerance. J Immunol Res. 2015;2015:981328.
XXXV. Al-Karawi AS, Rasool KH, Atoom AM, Kadhim AS. Correlation between H. pylori infection and serum levels of inflammatory markers: A retrospective study. Al-Salam Journal for Medical Science. 2023;2(2):20-4.
XXXVI. Andersen LP, Wewer AV, Christiansen KM, Tvede M, Hansen JP, Henriksen FW, et al. The humoral immune response to Helicobacter pylori infection in children with recurrent abdominal pain. Apmis. 1994;102(6):457-64.
XXXVII. Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol. 2014;20(36):12753-66.
XXXVIII. Reyes VE. Helicobacter pylori and Its Role in Gastric Cancer. Microorganisms. 2023;11(5).
XXXIX. Fu HW, Lai YC. The Role of Helicobacter pylori Neutrophil-Activating Protein in the Pathogenesis of H. pylori and Beyond: From a Virulence Factor to Therapeutic Targets and Therapeutic Agents. Int J Mol Sci. 2022;24(1).
XL. Cheok YY, Tan GMY, Lee CYQ, Abdullah S, Looi CY, Wong WF. Innate Immunity Crosstalk with Helicobacter pylori: Pattern Recognition Receptors and Cellular Responses. Int J Mol Sci. 2022;23(14).
XLI. Shiu J, Blanchard TG. Dendritic cell function in the host response to Helicobacter pylori infection of the gastric mucosa. Pathog Dis. 2013;67(1):46-53.
XLII. Smith SM. Role of Toll-like receptors in Helicobacter pylori infection and immunity. World J Gastrointest Pathophysiol. 2014;5(3):133-46.
XLIII. Lee CYQ, Chan YT, Cheok YY, Tan GMY, Tang TF, Cheong HC, et al. Helicobacter pylori Infection Elicits Type I Interferon Response in Human Monocytes via Toll-Like Receptor 8 Signaling. J Immunol Res. 2022;2022:3861518.
XLIV. Cavalcanti YV, Brelaz MC, Neves JK, Ferraz JC, Pereira VR. Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. Pulm Med. 2012;2012:745483.
XLV. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:491.
XLVI. Okeke EB, Uzonna JE. The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells. Front Immunol. 2019;10:680.
XLVII. Kronsteiner B, Bassaganya-Riera J, Philipson N, Hontecillas R. Novel insights on the role of CD8+ T cells and cytotoxic responses during Helicobacter pylori infection. Gut Microbes. 2014;5(3):357-62.
XLVIII. Quiding-Järbrink M, Lundin BS, Lönroth H, Svennerholm AM. CD4+ and CD8+ T cell responses in Helicobacter pylori-infected individuals. Clin Exp Immunol. 2001;123(1):81-7.
XLIX. Nurgalieva ZZ, Conner ME, Opekun AR, Zheng CQ, Elliott SN, Ernst PB, et al. B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect Immun. 2005;73(5):2999-3006.
L. Reyes VE, Peniche AG. Helicobacter pylori Deregulates T and B Cell Signaling to Trigger Immune Evasion. Curr Top Microbiol Immunol. 2019;421:229-65.
LI. Hua JS, Khin MM, Zheng PY, Yeoh KG, Ng HC, Bow H. Serum IgG response to differentiated antigens of Helicobacter pylori. World J Gastroenterol. 1998;4(3):249-51.
LII. Srivastava R, Kashyap A, Kumar M, Nath G, Jain AK. Mucosal IgA & IL-1β in Helicobacter pylori Infection. Indian J Clin Biochem. 2013;28(1):19-23.
LIII. Herbrink P, van Doorn LJ. Serological methods for diagnosis of Helicobacter pylori infection and monitoring of eradication therapy. Eur J Clin Microbiol Infect Dis. 2000;19(3):164-73.
LIV. Islam K, Khalil I, Ahsan CR, Yasmin M, Nessa J. Analysis of immune responses against H pylori in rabbits. World J Gastroenterol. 2007;13(4):600-6.
LV. Martin-Nuñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Front Endocrinol (Lausanne). 2021;12:639856.
LVI. Fakharian F, Asgari B, Nabavi-Rad A, Sadeghi A, Soleimani N, Yadegar A, et al. The interplay between Helicobacter pylori and the gut microbiota: An emerging driver influencing the immune system homeostasis and gastric carcinogenesis. Front Cell Infect Microbiol. 2022;12:953718.
LVII. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012;3(1):4-14.
LVIII. Lamb A, Chen LF. Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. J Cell Biochem. 2013;114(3):491-7.
LIX. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther. 2015;6(4):183-98.
LX. Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102(1):1-7.